JPRN-UMIN000020891招募中2 期
Phase II study of VAC1.2(vincristine, actinomycin-D, cyclophosphamide) followed by VA for patients with newly diagnosed low-risk subset A rhabdomyosarcoma - Phase II study of VAC1.2/VA therapy for patients with newly diagnosed low-risk subset A rhabdomyosarcoma
Japan Rhabdomyosarcoma Study Group0 个研究点目标入组 22 人开始时间: 2016年3月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 22
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 30years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients with central nervus system primary or metastatic tumors 2) Patients with synchronous or metachrounous concomitant malignancies 3) Patients with Charcot-Marie-Tooth disease or varicella 4) Patients with uncontrollable complications Interstitial pneumonia, pulmonary fibrosis, severe emphysema Uncontrollable diabetes mellitus Uncontrollable hypertension Severe electrocardiogram abnormality or clinically significant heart disease(heart failure, myocardial infarction, angina pectoris) Liver failure, cirrhosis Renal failure 5) Patients with contraindication of drugs used in this study 6) Female patints who are pregnant or breastfeeding mother or patients considering pregnancy 7) Patients with any other inappropriate conditon judged by physician
研究者
相似试验
招募中
2 期
Phase II study of VAC1.2/VA therapy for patients with newly diagnosed low-risk subset A rhabdomyosarcoma.RhabdomyosarcomaJPRN-jRCTs051180206Tsuchiya Kunihiko22
已完成
2 期
Phase II study of VAC1.2(vincristine, actinomycin-D, cyclophosphamide) therapy for patients with newly diagnosed low-risk subset A rhabdomyosarcoma.rhabdomyosarcomaJPRN-UMIN000039048Japan Rhabdomyosarcoma Study Group12
已完成
2 期
Phase II study of VAC2.2(vincristine, actinomycin-D, cyclophosphamide)/ VA(vincristine, actinomycin-D) therapy for patients with newly diagnosed low-risk subset B rhabdomyosarcoma.rhabdomyosarcomaJPRN-UMIN000039049Japan Rhabdomyosarcoma Study Group16
招募中
不适用
Phase II study of vincristine, actinomycin-D, cyclophosphamide and irinotecan for patients with newly diagnosed intermediate rhabdomyosarcoma.rhabdomyosarcomaJPRN-UMIN000023956Japan Rhabdomyosarcoma Study Group40
招募中
2 期
Phase II study of vincristine, actinomycin-D, cyclophosphamide and irinotecan for patients with newly diagnosed low-risk subset B rhabdomyosarcoma.rhabdomyosarcomaJPRN-UMIN000017004Japan Rhabdomyosarcoma Study Group18